EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Hepatotoxicity Profile of Bortezomib-Containing Regimens for First-Line Multiple Myeloma Treatment

Marko Lucijanic iD, Jerko Orec, Ena Soric, Anica Sabljic, Zeljko Jonjic, Mario Pirsic, Ozren Jaksic

Pharmaceuticals · 01.08.2026 · 19 (8) · 1205

DOI: 10.3390/ph19081205 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 01.08.2026. Verfasst von Marko Lucijanic und 6 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Department, University Hospital Dubrava, Avenija Gojka Suska 6, 10000 Zagreb, Croatia. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Bortezomib, a proteasome inhibitor, is one of the key agents in the first-line treatment of multiple myeloma (MM). Although its hepatotoxic potential has been described in case reports and registration trials, systematic real-life studies quantifying the incidence, dynamics and prognostic significance of liver injury during bortezomib-based therapy are lacking. We aimed to characterize the hepatotoxicity profile of first-line bortezomib-based regimens.

Methods

We retrospectively analyzed 115 consecutively treated MM patients at University Hospital Dubrava (2016–2023) who received first-line bortezomib-based regimens (VCD, VD, VMP, VRD, VTD). Liver function parameters (bilirubin, albumin, AST, ALT, GGT, ALP) were recorded at baseline and after 1 and 3 months, and abnormalities were graded according to CTCAE v5.0. Predictors of liver injury and its association with IMWG response and overall survival (OS) were assessed.

Results

Elevation of any liver transaminase was observed in 33% of patients at baseline, 40.2% at 1 month and 24% at 3 months. De novo worsening developed in 23.4% of patients, predominantly (88%) within the first month, with a dominantly cholestatic pattern (96%). Liver injury was not associated with the antimyeloma regimen, the class of supportive therapy, or most comorbidities (besides second malignancy for 3-month derangement), whereas higher tumor burden and baseline liver injury were identified among the predictors. Transaminase abnormalities were not associated with the likelihood of achieving a response, but liver injury at 3 months independently predicted shorter OS (HR 2.83; p = 0.011) after adjustment for age, sex and ISS stage.

Conclusions

Liver injury in bortezomib-treated MM patients is frequent and predominantly associated with the biology of the underlying disease rather than necessarily with the antimyeloma therapy itself; abnormalities persisting at 3 months deserve attention as an independent adverse prognostic marker.

Schlagwörter

Stichwörter der Autor:innen

bortezomibdrug safetydrug-induced liver injuryhepatotoxicitymultiple myelomaoverall survivalproteasome inhibitor

Autor:innen und Institutionen

  • Hematology Department, University Hospital Dubrava, Avenija Gojka Suska 6, 10000 Zagreb, Croatia.
  • School of Medicine, University of Zagreb, Salata 3, 10000 Zagreb, Croatia.
  • Scientific Research and Translational Medicine Department, University Hospital Dubrava, Avenija Gojka Suska 6, 10000 Zagreb, Croatia.

ORCID-Profile: Marko Lucijanic

Zitieren

APA

Lucijanic, M., Orec, J., Soric, E., Sabljic, A., Jonjic, Z., Pirsic, M., & Jaksic, O. (2026). Hepatotoxicity Profile of Bortezomib-Containing Regimens for First-Line Multiple Myeloma Treatment. Pharmaceuticals, 19(8), 1205. https://doi.org/10.3390/ph19081205

Vancouver

Lucijanic M, Orec J, Soric E, Sabljic A, Jonjic Z, Pirsic M, et al. Hepatotoxicity Profile of Bortezomib-Containing Regimens for First-Line Multiple Myeloma Treatment. Pharmaceuticals. 2026;19(8):1205. doi:10.3390/ph19081205

BibTeX
@article{Lucijanic2026,
  author = {Lucijanic, Marko and Orec, Jerko and Soric, Ena and Sabljic, Anica and Jonjic, Zeljko and Pirsic, Mario and Jaksic, Ozren},
  title = {Hepatotoxicity Profile of Bortezomib-Containing Regimens for First-Line Multiple Myeloma Treatment},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {8},
  pages = {1205},
  doi = {10.3390/ph19081205}
}
Kostenlos starten →